Business Context and Reporting Period
Company: The Gorman-Rupp Company
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2004
Business Overview: Manufacturer of pumps and fabricated products serving industrial, construction, and power generation markets.
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales | $49,431 | $43,903 |
| Gross Profit | $10,130 | $8,438 |
| Operating Income | $3,271 | $1,675 |
| Net Income | $2,207 | $1,202 |
| Earnings Per Share (Basic/Diluted) | $0.26 | $0.14 |
| Cash from Operating Activities | $4,551 | $3,652 |
| Cash and Cash Equivalents (Ending) | $18,033 | $14,052 |
| Current Ratio | 4.2 to 1 | 4.3 to 1 |
Margins: Gross margin improved to 20.5% (from 19.2% in 2003). Net income margin improved to 4.5% (from 2.7% in 2003).
Debt: No repayments to bank or note holders were recorded in Q1 2004. The company relies on internally generated funds and bank financing.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12.6% ($5.5 million) driven by higher product sales in industrial and construction markets. Pump product revenues rose 11.2%.
- Profitability: Net income surged 83.6% ($1.0 million) due to operating leverage and cost containment programs. Cost of products sold as a percentage of sales decreased to 79.5% from 80.8%.
- Backlog Decline: Order backlog decreased 18.8% to $56.4 million from $69.5 million a year ago, primarily due to a decline in fabricated products for the power generation market.
- Other Income: Decreased 19.9% due to less favorable foreign exchange valuation on inter-company transactions.
Guidance, Outlook, and Risks
Management Commentary: Management notes signs of economic recovery in industrial and construction sectors but highlights continued pressure from sluggish spending in the capital goods sector. The decline in fabricated product backlog appears to have leveled off.
Liquidity: The company maintains a strong liquidity position with a current ratio of 4.2 to 1 and adequate borrowing capacity. Capital expenditures are funded by internal cash flow.
Risks and Contingencies:
- Forward-looking statements are subject to risks including interest rates, capital spending, and competitor responses.
- Regulatory uncertainty regarding the Medicare Prescription Drug Improvement and Modernization Act of 2003 may impact postretirement benefit costs, though guidance is pending.
- Foreign operations are small and do not present material market risk; export sales are predominantly in U.S. dollars.
Investor Verification Checklist
- Verify the sustainability of the 12.6% sales growth given the 18.8% decline in order backlog.
- Monitor the impact of the pending accounting guidance for the Medicare Act on future postretirement benefit costs.
- Confirm the stability of the power generation market, which drove the backlog reduction.
- Review the effectiveness of cost containment programs in maintaining the improved gross margin of 20.5%.